Vaccine Safety

Encyclopedia of Virology

Volumn , Issue , 2008, Pages 226-235

  Clements, C J ^a   Lawrence, G ^b,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acceptability of immunization; Adjuvant; Adverse event following immunization; Aerosol vaccine; Anaphylaxis; Auto disable syringe; Avian leukocytosis virus; Bovine spongiform encephalitis; Causality assessment; Cell line; Chick embryo fibroblast; Clinical trial; Edible vaccine; Herpes virus; High titer measles vaccine; Immunization; Injection equipment; Measles mumps rubella vaccine; Neurovirulence test; Oncogenic; Poliovirus vaccine; Preservative; Programme error; Protective immunity; Regulatory authority; Rotavirus vaccine; Safety box; Stabilizer; SV40; Thermostability; Vaccination; Vaccine diluent; Vaccine safety

Indexed keywords

EID: 84875531456     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374410-4.00596-3     Document Type: Chapter

References (19)

1. Afzal M.A., Minor P.D., Schild G.C. Clinical safety of measles, mumps and rubella vaccine. Bulletin of the World Health Organization 2000, 78(2):199-204.
2. Bellaby P. Communication and miscommunication of risk: Understanding UK parents' attitudes to combined MMR vaccination. British Medical Journal 2003, 327:725-728.
3. Weekly Epidemiology Record, 23 March, 12 2001, 76:85-92. Causality assessment of adverse events following immunization, (accessed February 2007). http://www.who.int/vaccine_safety/reports/wer7612.pdf.
4. Clements C.J., McIntyre P.B. When science is not enough - A risk/benefit profile of thiomersal-containing vaccines. Expert Opinion on Drug Safety 2006, 5(1):17-29.
5. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: A review. Biologicals 1997, 25:323-338.
6. Dellepiane N., Griffiths E., Milstein J.B. New challenges in assuring vaccine quality. Bulletin of the World Health Organization 2000, 78:2155-2162.
7. Halsey N. Vaccine safety: Real and perceived issues. The Vaccine Book 2003, 371-385. Academic Press, Amsterdam. B.R. Bloom, P.-H. Lambert (Eds.).
8. Kharabsheh S., Al Otoum H., Clements C.J., et al. Mass psychogenic illness following Td vaccine in Jordan. Bulletin of the World Health Organization 2001, 79(8):764-770.
9. Madsen K.M., Lauritsen M.B., Pedersen C.B., et al. Thimerosal and the occurrence of autism: Negative ecological evidence from Danish population-based data. Pediatrics 2003, 112(3, Part 1):604-606.
10. Moss W.J., Clements C.J., Halsey N.A. Immunization of children at risk for infection with human immunodeficiency virus. Bulletin of the World Health Organization 2003, 81(1):61-70.
11. Safranek T.J., Lawrence D.N., Kurland L.T., et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Expert Neurology Group. American Journal of Epidemiology 1991, 133(9):940-951.
12. Shah K., Nathanson N. Human exposure to SV40: Review and comment. American Journal of Epidemiology 1976, 103:1-12.
13. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: A review. Bulletin of the World Health Organization 1999, 77(10):789-800.
14. Supplementary information on vaccine safety. Part 2: Background rates of adverse rates of adverse events following immunization. WHO/V&B/00.36 (accessed February 2007). http://www.who.int/vaccines-documents/DocsPDF00/www562.pdf.
15. Thompson N.P., Montgomery S.M., Pounder R.E., Wakefield A.J. Is measles vaccination a risk factor for inflammatory bowel disease?. Lancet 1995, 345:1071-1074.
16. Council for International Organizations of Medical Sciences (CIOMS) - WHO Working Group on Vaccine Pharmacovigilance. http://www.cioms.ch.
17. The Brighton Collaboration. http://www.brightoncollaboration.org.
18. The WHO Expert Committee on Biological Standardization; WHO Programme for International Drug Monitoring; WHO's Global Advisory Committee on Vaccine Safety (GACVS). http://www.who.int.
19. Uppsala Monitoring Centre (UMC), A WHO Collaborating Center. http://www.who-umc.org.